Clinical Research Directory

Inclusion Criteria: 1. Patients 18 years or older (no upper age limit) 2. Patients admitted for a first-ever or recurrent (occurred more than 1 year before) symptomatic supratentorial spontaneous ICH confirmed by brain imaging 3. Administration of study treatment no later than 48 hours after symptom onset or since last seen normal 4. Written consent obtained 5. Patient with social insurance in France 6. Patient willing to comply with all study procedures and duration Exclusion Criteria: 1. Massive ICH for Investigational medicinal product seems futile (hematoma volume is estimated \> 60ml) 2. Severe coma (Glasgow Coma Scale \<6) 3. Pure intraventricular hemorrhage 4. ICH suspected to result from a preceding trauma, an identified intracranial vascular malformation, venous thrombosis, tumor or hemorrhagic transformation within an infarct 5. Patient planned for surgical evacuation of ICH before randomization (Evacuation, Decompressive hemicraniectomy, External ventricular drain) 6. Patient with a known indication for DRF treatment (e.g. multiple sclerosis) or any other NrF2 agonist (dimethyl fumarate; Tecfidera) 7. Patient with contraindication to DRF: patients with known hypersensitivity to DRF, or to any of the excipients of VUMERITY (patients taking dimethyl fumarate) 8. Severe lymphopenia at admission (lymphocyte counts \< 0.5 x 109/L) 9. Medical history of progressive multifocal leukoencephalopathy 10. Severe swallowing disorder and/or nasogastric tube required 11. Severe pre-ICH dependency (modified Rankin score of 5) 12. Life expectancy \< 1 year related to comorbidities 13. Late-stage organ (acute cardiac, renal or hepatic failure) 14. Decision already taken for palliative (end of life) care with withdrawal of active treatment 15. Pregnancy or breastfeeding or Women of childbearing age without effective contraception (a pregnancy test will be done) 16. Adults who are deprived of their liberty by judicial or administrative decision